Governments and the scientific community are racing to identify new and existing drugs that might help flatten the curve and save lives. Read from experts as they discuss the latest news and research surrounding possible treatments for COVID-19.
Experts sent a letter to the White House Coronavirus Task Force March 24, outlining concerns about a growing shortage of medications required for managing patients with lupus and rheumatoid arthritis after President Donald Trump said in a March 19 press conference that the anti-malaria drug hydroxychloroquine could treat COVID-19.
As the number of patients infected with COVID-19 continues to rise, several experts are relaying data they say may save lives and change the course of this pandemic. According to Drs. George Martin, Ted Rosen, Sheila Fallon-Friedlander, Albert Yan, and James Treat, recent data provides evidence of the use of HCQ, its dosing, as well as epidemiology insights that will serve all healthcare practitioners in the fight against the novel coronavirus, COVID-19.
As the national pandemic continues to escalate, the American Academy of Dermatology is actively compiling resources related to the novel coronavirus to support its members and their practices.
The American Academy of Dermatology (AAD) has issued interim recommendations for practitioners to balance the risk of immunosuppression with the risk of disease flare amid COVID-19 pandemic.
Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.
By the end of a three-day weekend, five of the teams at Hacking Dermatology's 2019 Hackathon walked away with $5,000 each. Learn more about the collaboration that took place and the solutions each team developed to solve pressing problem areas in dermatology.
Merz announced the launch of Belotero Revive, Friday, April 5, in selected countries in Europe and Latin America.
New drugs, data and guidelines on acne and rosacea treatment were among the takeaways from days two and three of MauiDerm 2014. Presenters also described evidence-based suggestions for managing pigmentary disorders and updated information on infectious diseases.
We now have three neurotoxins in our marketplace. Do you feel that these neurotoxins differ, and if so, how? An expert panel addresses the topic at the 2013 Vegas Cosmetic Surgery and Aesthetic Dermatology meeting.